Furthermore, in contrast to our findings, LAG-3 expression assessed via CyTOF analysis was not associated with response to neoadjuvant nivolumab and relatlimab combination immunotherapy in patients with resectable melanoma.21 Therefore, further studies are required to elucidate the predictive value of LAG-3 alone, and together with PD-L1, in early and advanced stage melanoma. Here, LAG3 is linked to melanoma.